Stem cell-extracellular vesicles as drug delivery systems: New frontiers for silk/curcumin nanoparticles

Perteghella, Sara; Crivelli, Barbara; Catenacci, Laura; Sorrenti, Milena; Bruni, Giovanna; Necchi, Vittorio; Vigani, Barbara; Sorlini, Marzio; Torre, Maria Luisa; Chlapanidas, Theodora

doi:10.1016/j.ijpharm.2017.02.005

Cited by 76 publications

(49 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our results revealed that remarkably high encapsulation (>97 %) and loading (10% -80%) efficiency of CUR can be achieved in the CMSPs fabrication process, while typical loading efficiency for hydrophobic compound loading in protein nanoparticles is around 5% [47][48][49][50][51] .This phenomenon could owe to the strong hydrophobic interaction between hydrophobic CUR and the water-insoluble silk-II structure formed during the salting-out process. Our results have shown significant improvement in loading efficiency (up to 80%) compared with 6% found for CUR-loading into SF/poly(L-lactic acid-co-e-caprolactone) (P(LLA-CL)) nanofibrous scaffolds 52 , 12% for the silk/CUR nanoparticles fabricated in supercritical CO2 53 , 15% for the SFPs reported by Li et al 54 , 30% for the silk/CUR nanoparticles produced by desolvation method 55 , as well as 10% loading efficiency for the paclitaxel loaded SFPs 56 . The lower loading efficiency in SFPs via desolvation method was due to the fact that CUR tend to dissolve in organic solvent instead of adsorb on SF nanoparticles SFPs.…”

Section: Discussionmentioning

confidence: 57%

Magnetic-Silk Core–Shell Nanoparticles as Potential Carriers for Targeted Delivery of Curcumin into Human Breast Cancer Cells

Song

Muthana

Mukherjee

et al. 2017

ACS Biomater. Sci. Eng.

View full text Add to dashboard Cite

Curcumin is a promising anti-cancer drug but its applications in cancer therapy are limited due to its poor solubility, short half-life and low bioavailability. In this paper, we present a curcumin loaded magnetic silk fibroin core-shell nanoparticle system for sustained release of curcumin into breast cancer cells. Curcumin loaded magnetic silk fibroin core-shell nanoparticles were fabricated by a simple salting-out method using sodium phosphate with magnetic nanoparticles. The size, zeta potential, encapsulation/ loading efficiency and curcumin release rate were controlled and optimised by regulating silk fibroin concentration, pH value of the phosphate solution and curcumin usage. Curcumin loaded magnetic silk fibroin core-shell nanoparticles showed enhanced cytotoxicity and higher cellular uptake in the human Caucasian breast adenocarcinoma cell line (MDA-MB-231cells) evidenced by MTT and cellular uptake assays. In addition, silk fibroin nanoparticles and magnetic silk fibroin nanoparticles without curcumin loaded were used as controls. The particles prepared using sodium phosphate showed significantly smaller diameter (90-350 nm) compared with those prepared using potassium phosphate, which possess a diameter range of 500-1200 nm. These smaller particles are superior for biomedical applications since such size range is particularly desired for cell internalization. In addition, the magnetic cores inside the particles provide possibility of using an external magnet for cancer targeting.

show abstract

Section: Discussionmentioning

confidence: 57%

Magnetic-Silk Core–Shell Nanoparticles as Potential Carriers for Targeted Delivery of Curcumin into Human Breast Cancer Cells

Song

Muthana

Mukherjee

et al. 2017

ACS Biomater. Sci. Eng.

View full text Add to dashboard Cite

show abstract

“…This combined biological-technological approach could represent a novel class of nanosystems, combining beneficial effects of both regenerative cell therapies and pharmaceutical nanomedicine, avoiding the use of viable replicating stem cells [49]. This evidence demonstrates that MSC-secretome can be used both as API and DDS; although human and veterinary clinical trials are still few, we are confident that many will start in the nearly future.…”

Section: Sara Perteghella * Elia Bari and Maria Luisa Torrementioning

confidence: 93%

Steering the Clinical Translation of Delivery Systems for Drugs and Health Products

Pignatello

Matricardi

2020

Pharmaceutics

View full text Add to dashboard Cite

Besides the feasibility for industrial scale-up, accelerating the translation from bench to bedside of new technological strategies for controlled delivery and targeting of drugs and other actives relevant for health management, such as medical devices and nutraceuticals, would benefit from an even earlier evaluation in pre-clinical models and clinical settings. At the same time, translational medicine also performs in the opposite direction, incorporating clinical needs and observations into scientific hypotheses and innovative technological proposals. With these aims, the sessions proposed for the 2019 CRS Italy Chapter Workshop will introduce the experience of Italian and worldwide researchers on how to foster the actual work in controlled release and drug delivery towards a reliable pre-clinical and clinical assessment.

show abstract

“…In another study, hucMSC-EVs loaded with vincristine provided more cytotoxicity than the free drug [104]. Perteghella et al used silk/curcumin to create nanoparticles with an average diameter of 100 nm and incubated MSCs with those nanoparticles [105]. MSCs could then produce and release EVs that encapsulated the silk/curcumin nanoparticles.…”

Section: Small-molecule Drugsmentioning

confidence: 99%

“…MSCs could then produce and release EVs that encapsulated the silk/curcumin nanoparticles. This strategy can be used for the delivery of curcumin [105]. In addition, Tian et al used engineered EXs that expressed alpha integrin-specific iRGD to load doxorubicin via electroporation and they demonstrated that doxorubicin was specifically delivered to tumor tissues, which resulted in the inhibition of tumor growth in mice [106].…”

Section: Small-molecule Drugsmentioning

confidence: 99%

Therapeutic Advances of Stem Cell-Derived Extracellular Vesicles in Regenerative Medicine

Yin

Liu

Shi

et al. 2020

Cells

View full text Add to dashboard Cite

Extracellular vesicles (EVs), which are the main paracrine components of stem cells, mimic the regenerative capacity of these cells. Stem cell-derived EVs (SC-EVs) have been used for the treatment of various forms of tissue injury in preclinical trials through maintenance of their stemness, induction of regenerative phenotypes, apoptosis inhibition, and immune regulation. The efficiency of SC-EVs may be enhanced by selecting the appropriate EV-producing cells and cell phenotypes, optimizing cell culture conditions for the production of optimal EVs, and further engineering the EVs produced to transport therapeutic and targeting molecules. Cells 2020, 9, 707 2 of 28 storage, immune rejection, gene mutation, and tumorigenesis or tumor promotion in vivo limit its application. Stem cell derived-EVs (SC-EVs), as the main paracrine executor, overcome most limitations of stem cell applications. SC-EVs have allowed major advances in preclinical or clinical studies.In this review, the potential therapeutic applications of SC-EVs in regenerative medicine are discussed and the underlying molecular mechanisms are explored. Some of the possibilities for improving their secretion and altering their components to improve their efficacy toward diverse indications and diseases are summarized. Stem Cell-Derived EVs in the Treatment of Damaged TissueNumerous preclinical trials have reported that SC-EVs can carry active molecules, such as proteins, lipids, and nucleic acids, and good therapeutic effects against various diseases regarding different systems, including the nervous system, respiratory system, circulatory system, digestive system, urinary system, and others, have been observed. Neurological SystemBrain trauma is a common event that can cause nerve damage and disability. EXs derived from human adipose mesenchymal stem cells (AdMSC-EXs) can significantly increase the number of neurons, reduce inflammation, improve sensory and cognitive function, and produce better effects than AdMSCs alone in rats that have incurred traumatic brain injury (TBI) [6]. Kim et al. indicated that systemic administration of CD63+CD81+ EVs produced by human bone marrow-derived stem cells (BMSC-EVs) decreased neuroinflammation 12 h after a TBI in a mouse model of TBI induced by a controlled cortical impact device [7]. They also found that BMSC-EV infusion preserved the pattern separation and spatial learning abilities of mice, which were demonstrated respectively by an object-based behavioral test and a water maze test [7].Stroke is the sudden rupture or occlusion of cerebral blood vessels that interrupts the blood supply. It is the main cause of death and disability in Chinese adults. Preclinical studies have shown that SC-EVs seem to be a promising candidate for stroke treatment. Xin et al. showed that infusion of BMSC-EXs enhanced oligodendrogenesis and neurogenesis, remodeled synapses, reduced the incidence of stroke, and accelerated the recovery of neurological functions in a rat model of stroke induced by transient middle cerebral artery occl...

show abstract

Stem cell-extracellular vesicles as drug delivery systems: New frontiers for silk/curcumin nanoparticles

Cited by 76 publications

References 50 publications

Magnetic-Silk Core–Shell Nanoparticles as Potential Carriers for Targeted Delivery of Curcumin into Human Breast Cancer Cells

Magnetic-Silk Core–Shell Nanoparticles as Potential Carriers for Targeted Delivery of Curcumin into Human Breast Cancer Cells

Steering the Clinical Translation of Delivery Systems for Drugs and Health Products

Therapeutic Advances of Stem Cell-Derived Extracellular Vesicles in Regenerative Medicine

Contact Info

Product

Resources

About